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Introduction
HPVs induce epithelial lesions ranging from warts to metastatic tumours 1 . Of the more than 200 characterized HPV strains 2 , most share a common gene architecture 3 . As the most well-recognized HPV oncoproteins, E6 and E7 are essential for tumourigenesis in some HPV + tumour models 4, 5, 6 .
Beyond the oncogenic pathways driven by E6 and E7, emerging evidence suggests that high-risk HPV strains play an important role in epigenomic regulation of tumourigenesis. These strains have a conserved sequence motif for the CTCF transcription factor 7 . CTCF binds to the episomal (circular and non-integrated) HPV at the position of this sequence motif and regulates the expression of E6 and E7 7 . CTCF and YY1 interact by forming a loop which represses the expression of E6 and E7 in episomal HPV 8 . HPV integration may disrupt this loop and thereby lead to upregulated E6 and E7. While over 80% of HPV + invasive cancers have integrated forms of HPV, benign papillomas usually have episomal HPV 3 .
CTCF has well-established roles in regulating the 3D conformation of the human genome 9 . CTCF binding sites mark the boundaries of topological domains by blocking loop extrusion through the cohesin complex 10 . Mutations disrupting CTCF binding sites reorganize chromatin, potentially enabling tumourigenesis 11, 12, 13 . Introduction of a new CTCF binding site by HPV integration could have oncogenic reverberations beyond the expression of E6 and E7 transcription, by affecting chromatin organization. Here, we investigate this scenario-examining how HPV integration in tumours results in local changes in gene expression and alternative splicing-and propose new pathways to tumourigenesis driven by these changes.
Results
2.1 CTCF binds a conserved sequence motif in the host-integrated HPV 2.1.1 A specific CTCF sequence motif occurs more frequently in tumourigenic HPV strains than any other motif
We searched tumourigenic HPV strains' genomes for conserved transcription factor sequence motifs. Specifically, we examined 18 HPV strains in TCGA head and neck squamous cell carcinoma (HNSC) 17 and cervical squamous cell carcinoma (CESC) 18 datasets. In each strain's genome, we calculated the enrichment of 518 JASPAR 16 transcription factor motifs ( Figure 1a ). To control false discovery rate over multiple comparisons, we used the Benjamini-Hochberg procedure 19 to attain q-values 20 . ZNF263 and CTCF motifs were enriched at the same genomic regions within several tumourigenic strains (q < 0.05). The CTCF sequence motif at position 2,916 of HPV16, however, occurred in the highest number of HPV strains (10/18 strains) compared to any other sequence motif ( Figure 1a ). This position also overlapped with ATAC-seq reads mapped to HPV16 in TCGA-BA-A4IH ( Figure 1a ). The HPV16 match's sequence TGGCACCACTTGGTGGTTA closely resembled the consensus CTCF binding sequence 16 , excepting two nucleotides written in bold (p = 0.00001; q = 0.21).
CTCF binds its conserved sequence motif in host-integrated HPV16
To test the function of the conserved CTCF motif in host-integrated HPV16, we performed ATACseq, CTCF ChIP-seq, and RNA-seq on 5 HPV16 + cell lines: 93-VU147T 21 (7 integration sites), Caski 22 (6 integration sites), HMS-001 23 (1 integration site), SCC-090 24 (1 integration site), and SiHa 25 (2 integration sites). In each cell line, the strongest CTCF ChIP-seq peak of the HPV genome aligned to the conserved CTCF sequence motif described above (Figure 1b, right) . The presence of both episomal and host-integrated HPV complicates the interpretation of HPV genomic signals. SiHa, however, does not contain episomal HPV 26, 27 . All of the ATAC-seq and RNA-seq SiHa fragments mapping to the integration site close to the conserved CTCF motif (HPV16:3,131), also partially mapped to chr13:73,503,424. This also occurred for 3 of the 21 unpaired CTCF ChIP-seq reads mapping to HPV16:3,131. In agreement with previous reports 26, 27 , these a CTCF EGR1 FOXB1 IRF7 RELA RREB1 YY1 ZNF263 FIMO score for motifs with FDR < 0.05 0 2,000 4,000 6,000
HPV genomic position (bp) 7, 904 ATAC-seq (FPM) in TCGA-BA-A4IH results suggest that the SiHa signal comes from the host-integrated HPV and that CTCF binding persists after HPV integration. In 4 out of the 5 cell lines, the second-strongest chromatin accessibility peak aligned to both the CTCF sequence motif and the CTCF ChIP-seq peak (Figure 1b, left) . HMS-001, where HPV integrates into the host genome incompletely 23 , provided the lone exception. In HMS-001, regions of HPV that did not integrate into the host lacked signal from ATAC-seq, which specifically excludes non-chromatinized DNA (Figure 1b , left). Since ChIP-seq includes chromatinized as well as non-chromatinized DNA, the HMS-001 CTCF ChIP-seq signal without associated ATAC-seq signal indicated that CTCF bound to episomal HPV ( Figure 1b ). Other CTCF peaks in HMS-001 (HPV16:7,750 and HPV16:31) overlap ATAC-seq peaks and may correspond to partially hostintegrated HPV.
HPV integration dysregulates chromatin accessibility and transcription

HPV dysregulates the local chromatin and transcriptome of TCGA-BA-A4IH tumour
Integration of HPV into the host genome generates chimeric sequences which partially map to the host genome and partially map to the virus genome. We characterized high-confidence HPV integration sites containing chimeric sequences (subsection 4.7). Of the TCGA HNSC patients, 9 have matched RNA-seq and ATAC-seq data 28 . Using the RNA-seq data, we identified an HPV integration site in TCGA-BA-A4IH at chr9:99,952,156. The transcriptome and chromatin accessibility of this patient differed greatly from the other 8 patients at the HPV integration site ( Figure 2 ). The other 8 patients lacked transcription (RPM < 1) or chromatin accessibility (FPM < 0.2) within 5 kbp of the integration site. TCGA-BA-A4IH, however, exhibited both active transcription and open chromatin (Figure 2a ). In fact, TCGA-BA-A4IH's chromatin accessibility and RNA expression exceeded the other 8 patients up to 400 kbp beyond the integration site ( Figure 2b ). Within those bounds, TCGA-BA-A4IH's chromatin accessibility peaks often had signal exceeding that of all 8 other patients (Figure 2c ).
HPV dysregulates local chromatin and transcriptome in HPV + cell lines
To investigate the generalizability of dysregulated chromatin and transcriptome in TCGA-BA-A4IH, we conducted a similar analysis on 5 HPV + lines. For each HPV integration site, we compared the cell line with integrated HPV to the other 4 cell lines without HPV at that genomic position. Only the cell line with HPV integration displayed strong expression of nearby genes (Figure 3a , top).
For each viral integration site, expression of the chimeric transcript occurred either only downstream (for 3 of the integration sites of 93-VU147T and 2 of the integration sites of Caski) or only upstream (the other 12 integration sites), never in both directions (Figure 2a ). Directional chimeric transcription suggests that only one end of the integrated virus drove expression that continued past the integration site into the host genome.
Since we identified the integration site by detecting chimeric transcripts in RNA-seq data, we expected to observe transcription of the host genome at the site of viral integration. Nevertheless, 2). Each column shows a 200 bp genomic window overlapping a peak in any of the 9 patients. We showed all 200 bp genomic windows with sliding windows of 50 bp if the window overlaps a peak. (Bottom): Difference of the values in TCGA-BA-A4IH and the most extreme value in the other 8 patients when TCGA-BA-A4IH had the most extreme value among the 9 patients. We used white when it was not the most extreme value. transcription of these regions necessitates an active viral-dependent mechanism, as they are not transcribed in HPV − cell types (Figure 3a , top). Among all HPV integration sites, expression of the viral-host chimera co-occurred with chromatin accessibility signal (Figure 3a , middle). The overlap of transcription and chromatin accessibility suggests that viral integration introduces cis-regulatory elements which actively transcribe the viral-host chimera. The consistent recruitment of CTCF at HPV integration sites in 5 different cell lines and altered CTCF binding around integration sites suggest that CTCF plays a role in integration-dependent HPV tumourigenesis (Figure 3a , bottom).
To understand the spatial effect of HPV integration on chromatin, we examined CTCF ChIP-seq and chromatin accessibility peaks in HMS-001 within 500 kbp of its chr20:47,031,760 integration site (Figure 3b -c). Some of the regions of inaccessible chromatin in 93-VU147T, Caski, SCC-090, and SiHa are accessible in HMS-001 within 400 kbp of this integration site. In most of these regions, HMS-001 had more accessible chromatin compared to any of the other 4 cell lines (Figure 3b , middle). For CTCF, however, some genomic regions showed enrichment and other genomic regions showed depletion in CTCF binding (Figure 3c ).
Integration of HPV dysregulates expression and alternative splicing of local genes
HPV integration alters gene expression
To determine whether HPV integration significantly changed gene expression, we examined changes in transcription of individual genes. We used two criteria to identify outlier changes in gene expression which occured due to HPV integration. First, we calculated expression fold change dividing log 2 TPM in the sample with HPV integrated at some locus (TPM HPV + ) by median TPM in samples without HPV integrated at that locus ( TPM other ). For an HPV + cell line, we only considered a gene an outlier if its expression fold change exceeded 2. This meant a log 2 fold change greater than 1:
Fold change measurement, however, does not reflect dispersion in the expression of each gene. Second, therefore, we also required the difference in TPM to exceed at least twice the standard deviation (SD) of TPM of that gene in other cell lines:
Out of the 17 HPV integration sites, 10 had upregulated genes only (expression fold change > 2), 3 had downregulated genes only (expression fold change < −2), and 1 (chr17:38,267,231 of 93-VU147T) had both upregulated and downregulated genes (Figure 4a , middle).
HPV integration sites alter gene splicing
Our results suggested that HPV integration increases chromatin accessibility and alters CTCF binding. Since chromatin-binding proteins, including CTCF, can modify gene splicing 29 , we investigated whether HPV integration affects alternative splicing of nearby genes. We quantified how the expression of each exon varies independent of the global expression of that gene (see subsubsection 4.2.2) 30 . For outlier exon expression, we again used a criterion of expression fold change > 2 compared to other cell lines: Instead of using the SD cutoff, here we conditioned on a statistical significance threshold of q < 0.2. HPV integration sites in Caski and SCC-090 displayed outlier expression of specific exons of genes within 500 kbp ( Figure 4c ). These results indicate that HPV integration can influence differential exon usage of neighbouring genes.
HPV modifies the epigenome and transcriptome within 100 kbp of integration sites
The dysregulation of gene expression and splicing near HPV integration sites may relate to altered chromatin structure. We investigated transcriptomic and epigenomic dysregulation upon HPV integration in the RNA-seq, ATAC-seq, and CTCF ChIP-seq data. At each integration site, we compared the genomic coverage of each assay for the cell line with HPV integration to the average in the other four cell lines:
This allowed us to distinguish sample-specific variability from variations due to HPV integration. We calculated RPM fold change (Equation 4) for all 10 kbp genomic windows around any HPV integration site. We calculated the same measurement for 10 random permutations of HPV integration sites. For each permutation, we moved the location of each HPV integration site in each cell line to a random integration site from another cell line, without replacement. We scrambled only the locations of the integration sites, leaving the assay data the same. For each assay, we conducted a two-sided t-test on the difference of RPM fold change in comparison of original versus permuted cell lines at every 10 kbp from the site of HPV integration. To control false discovery rate over multiple comparisons, we used the Benjamini-Hochberg method 19 to attain q-values 20 (Figure 5a ).
RNA-seq, ATAC-seq, and CTCF ChIP-seq significantly differed between the original and permuted measurements up to 100 kbp from the HPV integration sites (q < 0.05). HPV's effect size on transcription, chromatin accessibility, and CTCF binding diminished as distance from the HPV integration sites increased ( Figure 5a ).
We hypothesized that changes in epigenome and transcriptome occurred due to a specific feature of the integrated HPV, and would not just arise from any genomic insertion. Under this hypothesis, we expected that the integration of the 170 kbp EBV would not induce similar changes to HPV. Therefore, we investigated how the transcriptome and epigenome changed at the EBV integration sites of 4 lymphoblastoid cell lines: GM12873, GM12878, GM23248, and GM23338. Of these cell lines, ENCODE supplies all 3 of total RNA-seq data, DNase-seq data, and CTCF ChIP-seq data for only GM12878 and GM23338. To provide 3 experiments for each assay, we added total RNA-seq and DNA-seq data from GM23248 and CTCF ChIP-seq from GM12873. For each of the 3 assays, this allowed us to compare potential differences arising from EBV integration in GM12878 to 2 other EBV + lymphoblastoid cell lines (Figure 5b) . Unlike with HPV, we detected no significant difference in transcriptome or epigenome within 100 kbp of EBV integration sites (Figure 5b ). We observed more transcription around EBV integration sites, but no statistically significant difference after correcting for multiple comparisons (q > 0.37). GM12878 had less accessible chromatin and less CTCF binding compared to the other 2 lymphoblastoid cell lines when considering a larger region up to 500 kbp around EBV integration sites (q < 0.05). The magnitude of change, however, was relatively modest (RPM fold change of as much as −4) compared with the corresponding difference near HPV integration sites (RPM fold change of as much as 22) (Figure 5b ).
HPV integration dysregulates the local transcriptome of HPV + carcinomas
Both cell lines derived from HNSC (93-VU147T, HMS-001, and SCC-090) and cell lines derived from CESC (Caski and SiHa) displayed epigenomic and transcriptomic changes near HPV integration sites. To investigate how often outlier gene expression occurs due to biological variation other than HPV integration, we permuted RNA-seq data for these 5 cell lines, for TCGA HNSC samples, and for TCGA CESC samples. In both the three original datasets and in 10 corresponding permuted datasets each, we examined genes at thresholds y of expression fold change separated by intervals of 0.25. We identified the genes with expression exceeding y where |TPM HPV − TPM other | > 2SD (Figure 5c ).
The original datasets contained more outlier genes passing a fold change cutoff of 2 compared to the 10 permuted controls. The greatest deviation of the original datasets compared to the permuted datasets occurred within the 100 kbp window of HPV integration. In the 5 cell lines examined, we detected 8 outlier genes within 100 kbp of HPV integration, but a mean of 5 outlier genes in the 10 permuted datasets. Among HNSC tumours, we identified 19 outlier genes, far greater than the mean of 4 outlier genes in the permuted HNSC controls. We also identified 90 outlier genes among CESC tumours-as opposed to a mean of 20 outlier genes within the permuted CESC controls.
We performed a similar permutation analysis to investigate whether differential exon usage occurs due to biological variations other than HPV integration (Figure 5d ). Within 100 kbp of HPV integration, we consistently identified more genes with differential exon usage in the original datasets compared to permuted controls. In the 5 cell lines examined, we found 8 genes with differential exon usage, but only a mean of 2 genes with differential exon usage among the permuted controls. In these 8 genes, absolute log 2 exon count fold change (Equation 3) exceeded 13 (q < 0.2). We found similar results for HNSC and CESC tumours.
HPV integration upregulates putative oncogenes
Having established that HPV integration results in changes in chromatin structure and dysregulated gene expression in cancer cell lines and patient tumours, we asked whether outlier expressed genes could play a driving role in tumourigenesis. We investigated the transcriptome of HPV + HNSC and CESC tumours in TCGA. Out of the 58 HNSC patients we examined, we found HPV integration sites in 26 of them by detecting transcribed chimeric sequences. Of these 26 patients, 16 (62%) displayed outlier expression of genes around HPV integration sites (Figure 6a ). Among 295 CESC patients, 134 had transcribed chimeric sequences and therefore HPV integration sites. Of those 134 patients, 64 (48%) tumours displayed outlier expression of genes around HPV integration sites (Figure 6b) .
Among the 5 cell lines, 16 HNSC tumours, and 64 CESC tumours, 231 genes in total showed outlier expression. Of these genes, 41 (18%) had Gene Ontology annotations 32, 33 for transcription factor DNA binding proteins (q = 0.002; one-sided Fisher's exact test). HNSC patient TCGA-BA-5559, however, had an HPV integration at chr19:52,384,802, which disrupted the expression of 10 transcription factors with zinc finger domains (Figure 6a ). Many genes with outlier expression around HPV integration sites, such as NME1 34 , FOXA1 35 , BCL2 36 , KLF12 37 , FGF3 38 , and PBX1 39 have previously reported roles in tumourigenesis.
Project Achilles 40 provides CRISPR-Cas9 screening data on the essentiality of 18,333 genes for the viability of 625 cancer cell lines. This includes 4 HPV + cell lines (SiHa, Caski, SISO 41 , and SCC-152 24 ). These datasets report a CERES score for each gene, which quantifies its essentiality for cancer proliferation and survival 40 . Non-essential genes have a median CERES score of 0 and common core essential genes have a median CERES score of −1.
Among the 193 upregulated genes around the integration sites of 80 HPV + patient tumours, 188 genes had negative CERES scores. For each patient, we performed 10 random permutations on the identity of the genes around their HPV integration sites, replacing them with other genes upregulated specifically in that patient (expression fold change > 2). Regardless of CERES score threshold used, we always found a higher number of upregulated essential genes in the original dataset than any of the permutation controls (Figure 6c ). Also, more patient tumours had at least one upregulated essential gene around their HPV integration site, compared to randomly selected upregulated genes (Figure 6d ).
Discussion
Several hypotheses can explain how HPV integration promotes tumourigenesis. Integration induces the expression of E6 and E7 either through disruption of the viral DNA-binding protein E2 42 , disruption of untranslated regions of E6 and E7 42 , or the creation of stable viral-host fusion transcripts 43 . Alternatively, certain integration sites may become genomically unstable, facilitating aberrant chromosomal rearrangements 23 or may activate the expression of transposable elements, particularly short interspersed nuclear elements (SINEs) 44 . Consistent with prior reports 23, 44, 45 , our results point to a separate mechanism whereby HPV integration leads to altered expression and splicing of neighbouring genes. Moreover, we identified active reorganization of local chromatin by CTCF binding to integrated HPV as a potential driver of local transcriptome dysregulation. For the first time, we showed that HPV integration itself alters chromatin accessibility and the transcriptome in cell lines and patients. These changes may contribute to tumourigenesis by upregulating the expression of neighbouring genes, including some essential to tumour viability. In individual HPV integration sites, outlier expression of genes and changes in the epigenome occurred within 400 kbp of the integration. Examining integration sites in cell lines and patient tumours collectively uncovered significant chromatin, expression, and splicing differences within 100 kbp.
We identified a possible role for CTCF binding to integrated HPV in dysregulating the host chromatin and transcriptome. A conserved CTCF binding site distinguishes tumourigenic and non-tumourigenic HPVs 7 . In episomal HPV, knockout of this binding site enhances the expression of the E6 and E7 oncogenes 8 . A distinct role of the binding site in integrated HPV resolves this apparent paradox and explains its recurrence in tumourigenic strains.
Introduction of a new CTCF binding site by HPV may re-organize existing host topological domains. This can explain the extent of the changes in the chromatin and transcriptome seen here 9 . CTCF binding also plays a role in the life cycle of other DNA viruses, such as EBV and Kaposi's sarcoma-associated herpesvirus 46 . We showed here, however, EBV integration does not lead to significant changes in chromatin at integration sites-only HPV integration does. Our data agree with previous work showing that only some changes to CTCF binding sites alter chromosome conformation 47, 48 .
We showed that HPV integration can increase the expression of neighbouring genes. We hypothesized that this, in turn, can predispose the host to tumour development. If true, the genomic position of the HPV integration site and the identity of its neighbouring genes should matter. Otherwise, we would expect HPV found in cancers integrated into genomic regions without any neighbouring oncogenes, since only a fraction of all genes can promote tumourigenesis. Reports on hotspot genomic regions in the host genome where HPV integrated 23, 44 and upregulated oncogenes around HPV integration sites 49 support the hypothesis of increased local expression. The enrichment of HPV integration sites around genes and transposable elements, especially SINEs 44 , also supports this hypothesis.
If dysregulation of gene expression by HPV integration contributes to tumour development, we would expect to identify known oncogenes and master regulators of cancer-related pathways among the dysregulated genes in our analysis. We found that 41/231 outlier genes had the Gene Ontology annotation for transcription factor DNA binding proteins. Upregulated genes around HPV integration sites enriched among the most essential genes compared to upregulated genes distant from HPV integration sites.
Most of the tumours we examined had chimeric transcripts that pinpointed integration sites. Only investigating these integration sites eliminated the possibility of detecting false positive integration sites. This approach, however, can miss some true integration sites where one read of a pair maps completely to the virus and the other completely to the host. Future studies with targeted approaches such as Tagmentation-assisted Multiplex PCR Enrichment sequencing (TaME-seq) could identify HPV integration sites more exhaustively 50 .
Regardless of these limitations, our results show that integration of HPV induces changes in local chromatin of the host and the local transcriptome. We predicted that these changes contribute to tumourigenesis. Our results suggest that interactions between integrated HPV chromatin and host chromatin triggers these changes and that CTCF may play a key role in this process. Understanding the underlying mechanism of HPV-host chromatin interactions and their essentiality in tumourigenesis will better focus the future development of therapies for HPV + cancers.
Methods
Genome assembly, annotations, and data processing
We generated a chimeric genome assembly and RefSeq gene transfer format (GTF) annotation of GRCh38 from Illumina iGenomes (https://support.illumina.com/sequencing/sequencing_ software/igenome.html) and the National Center for Biotechnology Information (NCBI) RefSeq HPV16 K02718.1 assembly 51 . The resulting chimeric FASTA file had all the GRCh38 chromosomes, unplaced and unlocalized contigs, chrM (mitochondrial genome), EBV, and one additional chromosome containing the entire K02718.1 sequence. The GTF file contained all the Illumina iGenomes GRCh38 annotations and additional rows annotating K02718.1 coding sequences. For all experiments, we trimmed Illumina TruSeq adapters from FASTQ files with Trim Galore (version 0.4.4, https://www.bioinformatics.babraham.ac.uk/projects/trim_galore).
For CTCF ChIP-seq, input control ChIP-seq, and ATAC-seq, we used Bowtie2 52 (version 2.2.6) with default parameters to align FASTQ files to the chimeric GRCh38-HPV16 genome. For RNA-seq, we used STAR (version 2.6.0c) 53 , specifying options --outFilterMultimapNmax 2 --genomeSAindexNbases 6 --alignSJoverhangMin 8 --alignSJDBoverhangMin 4 --outFilterMismatchNoverReadLmax 0.05 to align the FASTQ files to the chimeric GRCh38-HPV16 genome.
RNA-seq
Library preparation and sequencing
We prepared samples for RNA-seq using the TruSeq Stranded Total RNA Sample Preparation kit with RiboZero Gold (Illumina, San Diego, CA). We performed RNA sequencing for each sample to ∼80 million paired-end 150 bp reads on an Illumina NextSeq 500 (Princess Margaret Genomics Centre, Toronto, ON). We collected input RNA using an AllPrep mini kit (Qiagen, Hilden, Germany).
Bioinformatics analysis
We used StringTie 54 (version 1.3.3b) to quantify TPM for genes in the chimeric GRCh38 annotation. We used DEXSeq (version 1.28.1) for alternative isoform analysis 30 . For DEXSeq, we downloaded Ensembl genes version 94 for compatibility with the DEXSeq protocol 55 . For each gene, we compared each sample against all the other samples. We repeated these steps for cell lines, HNSC, and CESC patients.
We generated a list of the exons with the most extreme difference in expression according to the DEXSeq negative binomial generalized linear model for all the genes around HPV integration sites. We corrected the p-values for multiple testing using the Benjamini-Hochberg method 19 and used a cutoff of q < 0.2 and minimum absolute fold change of 2 to select genes with alternative isoform expression.
CTCF ChIP-seq
Library preparation
We prepared 10 µL of both protein A and protein G beads through three washes of 5 mg/mL Dulbecco's phosphate-buffered saline (dPBS) + bovine serum albumin (BSA). We added 10 µL of polyclonal CTCF antibody (Cat No. 2899, Lot 002, Cell Signalling Technology, Danvers, MA; RRID:AB 2086794) to the beads in 300 µL dPBS + BSA and left it to bind for >6 h of rotation at 4 • C. After incubation, we washed the beads three more times with dPBS + BSA. Then, we resuspended the beads in protease inhibitor (PI) and 100 µL of modified radioimmunoprecipitation assay buffer (RIPA): 10 mmol/L Tris-HCl, pH 8.0; 1 mmol/L EDTA; 140 mmol/L NaCl; 1% volume fraction Triton X-100; 0.1% mass fraction SDS; 0.1% mass fraction sodium deoxycholate.
We trypsinized 1 million cells and then fixed for 10 min at room temperature in 300 µL of dPBS + 1% volume fraction formaldehyde. We added 15 µL of 2.5 mol/L glycine after fixing. Then, we washed the cells once in PBS + PI before resuspending them in 300 µL of modified RIPA + PI. We sonicated the samples for 32 cycles of 30 s at full intensity using a Bioruptor Pico (Diagenode, Seraing, Belgium) and pelleted cell debris by spinning at 21,130 ×g for 15 min. We set aside 15 µL of the supernatant as an input control, and diluted the remaining supernatant with 1700 µL of modified RIPA + PI and 100 µL of washed beads. We incubated the samples at 4 • C overnight with rotation. We washed the beads with the following cold buffers in order: modified RIPA, modified RIPA + 500 µmol/L NaCl, LiCl buffer (10 mmol/L Tris-HCl, pH 8.0; 1 1 mmol/L EDTA; 250 mmol/L LiCl; 0.5% mass NP-40; 0.5% mass sodium deoxycholate), and finally twice with TE buffer (pH 8.0). We resuspended the samples and inputs in 100 µL of de-crosslinking buffer (1% volume fraction SDS, 0.1 mol/L NaHCO 3 ) and incubated at 65 • C for 6 h. We cleaned the samples and inputs using the Monarch PCR & DNA clean-up kit (New England BioLabs, Ipswich, MA), prepared libraries using the ThruPLEX DNA-seq Kit (Rubicon Genomics, Ann Arbor, MI), and size selected to 240 bp-360 bp using a PippinHT 2% Agarose Cassette (Sage Science, Beverly, MA). For each sample, we sequenced three ChIP biological replicates and one input control to ∼25 million single-end 50 bp reads each on an Illumina HiSeq 2000 (Princess Margaret Genomics Core, Toronto, ON).
Bioinformatics analysis
We used MACS2 (version 2.1.2) software 56 to identify peaks and generate fragment pileup data using default parameters plus --nomodel --bdg, and using input as control. We also generated a log fold change enrichment bedGraph file by comparing fragment pileup to the input control lambda file generated by MACS2.
We used FASTQC 57 (version 0.11.5) to assess the quality of ChIP-seq FASTQ files. After alignment with Bowtie2 and peak calling with MACS2, we used ChIPQC 58 (version 1.18.2) to assess enrichment quality. Input controls always had less than 0.7% fraction of reads in peaks, while ChIP experiments had an average of 9.4% fraction of reads in peaks (SD 6.4%). We merged the three replicates and found the following number of peaks passing a threshold of 5% FDR! (FDR!) and 5-fold enrichment over input control: 32,748 in 93-VU147T, 22,353 in Caski, 35,861 in HMS-001, 27,469 in SCC-090, and 37,161 in SiHa.
ATAC-seq
Library preparation and sequencing
We assessed open chromatin using OMNI-ATAC 59 followed by size selection to 100 bp-600 bp using a PippinHT 2% Agarose Cassette (Sage Science, Beverly, MA) and paired-end 125 bp sequencing on an Illumina HiSeq 2500 to a depth of ∼60 million reads per sample (Princess Margaret Genomics Core, Toronto, ON).
Bioinformatics analysis
We used MACS2 (version 2.1.2) software 56 to identify peaks and generate fragment pileup data using default parameters and --nomodel --shift -100 --extsize 200 --bdg --bampe. For analysis of ATAC-seq peaks, we used a false discovery rate threshold of 5%.
To visualize the chromatin accessibility signal of multiple samples at HPV integration sites, we used the FPM measurement of each sample divided to the maximum FPM of that sample in the chromosome of HPV integration. This ensured all of the values ranged between 0 and 1 in that chromosome.
TCGA datasets and analysis
RNA-seq datasets
We downloaded GRCh37-aligned TCGA RNA-seq datasets for 295 CESC patients and 547 HNSC patients 28 . We extracted FASTQ files from the binary alignment map (BAM) files using bam2fastq (https://gsl.hudsonalpha.org/information/software/bam2fastq). We aligned the samples back to the chimeric GRCh38-HPV16 genome using STAR 53 .
We used StringTie 54 to quantify TPM for each of the experiments according to the chimeric GTF annotation of GRCh38 and HPV16. From the available 547 HNSC patients, we identified 58 as HPV + . We identified all of the 295 CESC patients as HPV + . We used DEXSeq for alternative isoform analysis 30 .
ATAC-seq datasets
For the 9 TCGA HNSC patients with ATAC-seq data, we downloaded GRCh38-aligned BAM files. We extracted FASTQ files from the BAM files using bam2fastq (version 1.1.0, https:// gsl.hudsonalpha.org/information/software/bam2fastq), trimmed adapters and low-quality sequencing reads from the FASTQ files with Trim Galore, and aligned the samples back to the chimeric GRCh38-HPV16 genome using Bowtie2 52 (version 2.2.6). We used MACS2 (version 2.1.2) software 56 to identify peaks and generate fragment pileup data using default parameters and --nomodel --shift -100 --extsize 200 --bdg --bampe. For any analysis on ATAC-seq peaks, we used a false discovery rate threshold of 5%.
Identifying HPV strains
For HNSC and CESC patients, we mapped the sequencing reads to a reference genome of 189 HPV strains using Bowtie2 52 (version 2.2.6) with --local. We considered the HPV strain with the highest number of mapped reads as the dominant strain.
Identifying HPV integration sites
We developed Bellerophon to identify HPV integration sites with chimeric sequencing reads from any paired-end sequencing data. First, Bellerophon aligns reads to a viral genome. It allows for partial mapping using local alignment, and removes any sequencing fragment where neither read maps to the virus. Second, Bellerophon aligns the selected reads to the host genome, permitting partial mapping. Third, Bellerophon identifies chimeric reads: those reads mapped partially to the host genome and partially to the virus genome. Fourth, for each chimeric read, Bellerophon reports the start and strand of integration in both the host and viral genomes. Bellerophon also reports the number of chimeric reads supporting each integration site.
Bellerophon finds highly confident integration sites which contain chimeric sequencing reads. Other methods perform the first two steps in reverse order 60 , resulting in slower performance. While some previous methods also align to the virus first 61 , either the software no longer appears available where specified at publication 62,63 , or they use BLAST 64,65 instead of a faster short read aligner 66 . Unlike ViFi 44 , Bellerophon requires that the chimera match an existing viral genome reference.
Bellerophon does not use non-chimeric fragments where one read maps entirely to host and one read maps entirely to virus genome.
Bellerophon uses Bowtie2 52 (version 2.2.6) and vastly speeds up integration site finding. Bellerophon identified integration sites at an average of 8 core-hours on a 2.6 GHz Intel Xeon CPU E5-2650 v2 processor and 4 GB of RAM for whole genome sequencing data. Previous methods 67 require an average of 400 CPU core-hours.
We identified HPV integration sites in each sample using the sequence of the dominant HPV strain in that sample. We excluded any HPV integration site found in more than 1 patient to avoid overestimation of outliers at potential genomic hotspots of frequent integration 23 . In some cases, we found more than one HPV integration site in a 20 kbp window in one patient. Since we used RNA-seq for identifying our integration sites, some of these integration sites might occur as a result of splicing between the integrated HPV and neighbouring host genomic regions. To avoid over-representing genomic regions with multiple integration sites, we only used the integration site with the highest number of chimeric sequencing reads.
